Breakdown | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 96.36B | 73.02B | 49.60B | 31.90B | 30.36B |
Gross Profit | 21.11B | 15.41B | 10.37B | 7.66B | 7.13B |
EBITDA | 16.95B | 11.72B | 7.70B | 4.78B | 3.77B |
Net Income | 10.20B | 7.98B | 5.81B | 3.29B | 2.62B |
Balance Sheet | |||||
Total Assets | 116.78B | 70.60B | 41.92B | 27.09B | 24.76B |
Cash, Cash Equivalents and Short-Term Investments | 17.33B | 12.14B | 14.12B | 10.08B | 9.86B |
Total Debt | 53.20B | 22.40B | 3.47B | 2.69B | 2.63B |
Total Liabilities | 79.77B | 41.68B | 20.52B | 11.16B | 11.57B |
Stockholders Equity | 37.01B | 28.92B | 21.40B | 15.93B | 13.19B |
Cash Flow | |||||
Free Cash Flow | -22.31B | -19.02B | 3.65B | 771.34M | 5.80B |
Operating Cash Flow | -18.73B | -18.66B | 4.68B | 1.13B | 5.96B |
Investing Cash Flow | -4.22B | 386.99M | 64.81M | 134.01M | -433.48M |
Financing Cash Flow | 27.18B | 17.45B | -24.90M | -881.82M | -937.84M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
81 Outperform | ¥96.84B | 9.63 | 2.68% | 11.77% | 2.77% | ||
79 Outperform | ¥21.44B | 12.91 | 3.17% | 5.39% | -0.34% | ||
77 Outperform | ¥120.38B | 11.20 | 2.64% | 48.98% | 39.43% | ||
77 Outperform | ¥95.17B | 11.29 | 3.06% | -0.98% | -18.48% | ||
74 Outperform | ¥122.47B | 21.52 | 3.69% | >-0.01% | -26.82% | ||
74 Outperform | ¥107.34B | 13.94 | 2.14% | 15.99% | 32.43% | ||
59 Neutral | AU$1.66B | 11.43 | -2.47% | 3.57% | 7.50% | 6.12% |
Nomura Micro Science Co., Ltd. announced the issuance of stock options to its executive officers and employees to align business performance with stock value and enhance motivation for long-term corporate value improvement. This move is expected to strengthen the company’s operational performance and market position by incentivizing key personnel to contribute to its growth.
Nomura Micro Science Co., Ltd. reported a significant increase in its consolidated financial results for the three months ending June 30, 2025, with net sales rising by 62.6% year-on-year. The company also saw substantial growth in operating profit and ordinary profit, indicating a strong recovery and positive momentum in its business operations.
Nomura Micro Science Co., Ltd. announced corrections to its FY2025 March Earnings Report due to errors in the consolidated cash flow statements. The corrections indicate a change in cash flows from operating and investing activities, impacting the company’s financial reporting and potentially affecting stakeholders’ perceptions of its financial health.
Nomura Micro Science Co., Ltd. has announced a change in the repayment dates for loans related to its large water treatment systems project. The repayment dates have been extended to February 27, 2026, from the original dates in mid-2025. This decision, made to better align with the company’s cash flow situation, is expected to have a minor impact on the company’s performance for FY2026.
Nomura Micro Science Co., Ltd. announced its decision to implement dividends of surplus with a record date of March 31, 2025. This decision aligns with the company’s medium-term management plan to maintain a balanced cash allocation and a target dividend payout ratio of 30%. The total annual dividends for the current term will be 80 yen per share, reflecting the company’s commitment to stable shareholder returns and a sound financial foundation.